Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MANTIS has been given the greenlight and is now open to recruitment.

 At present, there is little evidence for an effective drug in the treatment of Avascular Necrosis (AVN) of the femoral head. This is an uncommon yet devastating condition, primarily effecting a younger patient population. The MANTIS trial is a blinded, randomised, placebo controlled trial looking at the use of bisphosphonates and whether they can help to delay or prevent the progression of AVN.

 If you would like to be involved as a recruiting site, please contact or follow the trial on twitter for the latest news @mantis_trial

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.